---
title: "Eledon Pharmaceuticals Advances Kidney Transplant Study with Tegoprubart"
description: "Eledon Pharmaceuticals is conducting a Phase 2 clinical study, ‘AT-1501-K209: BESTOW-EXTENSION’, to evaluate the long-term safety and efficacy of Tegoprubart in kidney transplant recipients. The study"
type: "news"
locale: "en"
url: "https://longbridge.com/en/news/262950884.md"
published_at: "2025-10-27T19:10:38.000Z"
---

# Eledon Pharmaceuticals Advances Kidney Transplant Study with Tegoprubart

> Eledon Pharmaceuticals is conducting a Phase 2 clinical study, ‘AT-1501-K209: BESTOW-EXTENSION’, to evaluate the long-term safety and efficacy of Tegoprubart in kidney transplant recipients. The study compares Tegoprubart with Tacrolimus, focusing on preventing transplant rejection. It began on November 6, 2023, and aims to provide insights that could influence investor confidence and stock performance. The study is ongoing, with updates available on the ClinicalTrials portal.

Eledon Pharmaceuticals, Inc. is conducting a Phase 2 clinical study titled ‘AT-1501-K209: BESTOW-EXTENSION’ to assess the long-term safety and efficacy of Tegoprubart in kidney transplant recipients. The study aims to provide insights into the potential benefits of Tegoprubart over the commonly used drug Tacrolimus, focusing on preventing kidney transplant rejection.

The study tests two interventions: Tegoprubart (AT-1501) and Tacrolimus. Tegoprubart is administered intravenously every three weeks, while Tacrolimus is given orally with dosage adjustments to maintain specific blood levels. Both treatments are combined with other standard medications like MMF or MPS and corticosteroids.

This interventional study is non-randomized with a parallel assignment model, meaning participants are assigned to one of the two treatment groups. There is no masking involved, allowing both participants and researchers to know which treatment is being administered. The primary goal is treatment-focused.

The study began on November 6, 2023, with the latest update submitted on July 21, 2025. These dates are crucial as they indicate the study’s progress and timeline for potential results, which can impact market and investor decisions.

The update on this study could influence Eledon Pharmaceuticals’ stock performance, as positive outcomes may enhance investor confidence and position the company favorably against competitors in the kidney transplant treatment market.

The study is ongoing, with further details available on the ClinicalTrials portal.

### Related Stocks

- [ELDN.US - Eledon Pharmaceuticals](https://longbridge.com/en/quote/ELDN.US.md)

## Related News & Research

| Title | Description | URL |
|-------|-------------|-----|
| Eledon Pharmaceuticals Highlights BESTOW Data, Phase III Plans and FDA Timeline for “Tego” at Conference | Eledon Pharmaceuticals (NASDAQ:ELDN) executives presented data from the Phase II BESTOW kidney transplant study and outl | [Link](https://longbridge.com/en/news/275931982.md) |
| Eledon Pharmaceuticals: Promising Kidney Transplant Program and Strong Financial Position Support Buy Rating | LifeSci Capital's Rami Katkhuda maintains a Buy rating on Eledon Pharmaceuticals, citing promising kidney transplant pro | [Link](https://longbridge.com/en/news/266087010.md) |
| Maze Therapeutics Highlights Upcoming MZE829 Kidney Data, Maps Phase 2 Plans for MZE782 at Summit | Maze Therapeutics (NASDAQ: MAZE) is advancing a genetics-driven drug development approach, focusing on kidney and metabo | [Link](https://longbridge.com/en/news/275972996.md) |
| National Donor Day Spotlight: DaVita Patient Care Technician Donates Kidney | On National Donor Day, DaVita highlights Holly, a patient care technician who donated her kidney. After her husband Hest | [Link](https://longbridge.com/en/news/275937358.md) |
| Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says | Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says | [Link](https://longbridge.com/en/news/275926557.md) |

---

> **Disclaimer**: This article is for reference only and does not constitute any investment advice.
